Prof. Philipp Beckhove, Scientific Director of the LIT, was guest in the podcast “Tonspur Wissen” by Leibniz Association and Rheinische Post. He talked with journalist Ursula Weidenfeld about new developments in fighting cancer with immunotherapy (in German).
Researchers at the Leibniz Institute for Immunotherapy (LIT) studied hundreds of patients with acute myeloid leukemia (AML). They discovered that specific mutations in the STAG2 protein cause altered DNA folding in the cell nucleus, thereby contributing to the development of AML.
Researchers at the Leibniz Institute for Immunotherapy (LIT), University Hospital Regensburg (UKR) and the National Heart, Lung, and Blood Institute (NHLBI) have engineered CD8+ T cells to artificially express the gene LMO4, thereby enhancing their effectiveness against tumors.
Researchers at the Leibniz Institute for Immunotherapy (LIT) describe a new type of regulation of immune cells by so-called ‘jumping genes.’
Due to exemplary actions in the field of equal opportunity-oriented personnel and organizational policies, Leibniz Institute for Immunotherapy is awarded the TOTAL E-QUALITY award for the second time, which is valid for the years 2024 to 2026.
More than 150 leading scientists from around the world discussed latest developments in immunological research and the treatment of diseases such as cancer, autoimmune diseases, and chronic inflammation at the International Symposium of the Leibniz Institute for Immunotherapy June 26th – 27th, 2024 in Regensburg.
Cell and Gene therapy experts from the international consortium ‘CAR T Cells Rewired to Prevent EXhaustion in the Tumour Microenvironment’ (CAR T-REX) gathered on the 28 and 29 May for a General Assembly at CiQUS, Universidade de Santiago de Compostela.
Leibniz scientists significantly involved in national strategy for gene and cell-based therapies.
Luca Gattinoni and Matthias Edinger from the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) have received a 2.6 million euro grant from the German Cancer Aid. The funding will support an innovative clinical study using stem-like CAR T cells to treat patients with advanced lymphomas.
The International LIT Symposium takes place June 26th – 27th, 2024 in Regensburg, Germany.
